Overview Dividends

(CGEM) Cullinan Oncology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2300311063

Zipalertinib, CLN-978, CLN-619, CLN-049, CLN-617

Risk via 10d forecast
Volatility 64.8%
Value at Risk 5%th 98.3%
Relative Tail Risk -7.79%
Reward TTM
Sharpe Ratio -0.84
Alpha -64.77
Character TTM
Hurst Exponent 0.591
Beta 0.899
Beta Downside 0.330
Drawdowns 3y
Max DD 80.41%
Mean DD 39.36%
Median DD 35.04%

Description: CGEM Cullinan Oncology October 24, 2025

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a U.S. clinical-stage biotech focused on small-molecule and antibody therapeutics for oncology and autoimmune disorders. Its lead assets include zipalertinib (Phase 3 NSCLC), CLN-978 (T-cell engager for SLE and RA), and CLN-619 (monoclonal antibody in Phase 1 for solid tumors and multiple myeloma). Additional pipelines are CLN-049 (bispecific antibody for AML/MDS and MRD-positive AML) and CLN-617 (fusion protein for solid tumors). The company collaborates with Adimab on antibody discovery and with Taiho Pharmaceutical on zipalertinib co-development. Formerly Cullinan Oncology, the firm rebranded to Cullinan Therapeutics in April 2024 and is headquartered in Cambridge, MA.

Key market-level drivers that will shape CGEM’s upside include (i) the U.S. oncology market’s projected CAGR of ~8 % through 2030, (ii) FDA’s historically higher approval rates for Phase 3 trials in NSCLC (~30 % in the last five years), and (iii) the company’s cash runway, which, according to its most recent 10-Q, was sufficient for ~12 months of operating expenses-though exact burn-rate figures are not disclosed publicly, introducing uncertainty around near-term financing needs.

If you want a data-rich, quantitative view of CGEM’s valuation and risk profile, the ValueRay analyst model provides a useful starting point for deeper research.

CGEM Stock Overview

Market Cap in USD 425m
Sub-Industry Biotechnology
IPO / Inception 2021-01-08
Return 12m vs S&P 500 -54.0%
Analyst Rating 4.89 of 5

CGEM Dividends

Currently no dividends paid

CGEM Growth Ratios

CAGR 3y -11.77%
CAGR/Max DD Calmar Ratio -0.15
CAGR/Mean DD Pain Ratio -0.30
Current Volume 649k
Average Volume 732.3k

Piotroski VR‑10 (Strict, 0-10) 0.0

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)
FCFTA -0.36 (>2.0%) and ΔFCFTA -16.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.36 (>3.0%) and CFO -174.3m > Net Income -216.8m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 10.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (59.0m) change vs 12m ago 1.16% (target <= -2.0% for YES)
error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)
Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -6.02 (EBITDA TTM -241.2m / Interest Expense TTM 30.9m) >= 6 (WARN >= 3)

Altman Z'' -18.82

(A) 0.64 = (Total Current Assets 342.2m - Total Current Liabilities 32.8m) / Total Assets 484.1m
(B) -1.11 = Retained Earnings (Balance) -537.4m / Total Assets 484.1m
warn (B) unusual magnitude: -1.11 — check mapping/units
(C) -0.33 = EBIT TTM -185.8m / Avg Total Assets 568.7m
(D) -16.38 = Book Value of Equity -536.4m / Total Liabilities 32.8m
Total Rating: -18.82 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 35.30

1. Piotroski 0.0pt = -5.0
2. FCF Yield data missing
3. FCF Margin data missing
4. Debt/Equity 0.00 = 2.50
5. Debt/Ebitda 0.42 = 2.36
6. ROIC - WACC (= -39.88)% = -12.50
7. RoE -41.58% = -2.50
8. Revenue Trend data missing
9. EPS Trend 8.81% = 0.44

What is the price of CGEM shares?

As of November 14, 2025, the stock is trading at USD 8.27 with a total of 648,997 shares traded.
Over the past week, the price has changed by +12.52%, over one month by +5.62%, over three months by +8.25% and over the past year by -47.63%.

Is Cullinan Oncology a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Cullinan Oncology (NASDAQ:CGEM) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 35.30 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CGEM is around 6.58 USD . This means that CGEM is currently overvalued and has a potential downside of -20.44%.

Is CGEM a buy, sell or hold?

Cullinan Oncology has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CGEM.
  • Strong Buy: 8
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CGEM price?

Issuer Target Up/Down from current
Wallstreet Target Price 25.9 213.1%
Analysts Target Price 25.9 213.1%
ValueRay Target Price 7.2 -13.4%

CGEM Fundamental Data Overview November 11, 2025

Market Cap USD = 424.8m (424.8m USD * 1.0 USD.USD)
P/E Forward = 6.3012
P/S = 26.8794
P/B = 0.6902
Beta = -0.068
Revenue TTM = 0.0 USD
EBIT TTM = -185.8m USD
EBITDA TTM = -241.2m USD
Long Term Debt = 2.15m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 1.19m USD (from shortTermDebt, last quarter)
Debt = 1.19m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.1m USD (from netDebt column, last quarter)
Enterprise Value = 93.4m USD (424.8m + Debt 1.19m - CCE 332.6m)
Interest Coverage Ratio = -6.02 (Ebit TTM -185.8m / Interest Expense TTM 30.9m)
FCF Yield = -186.7% (FCF TTM -174.3m / Enterprise Value 93.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 230.0k) / Revenue TTM)
Tobins Q-Ratio = 0.19 (Enterprise Value 93.4m / Total Assets 484.1m)
Interest Expense / Debt = 388.5% (Interest Expense 4.62m / Debt 1.19m)
Taxrate = -0.07% (negative due to tax credits) (117.0k / -167.5m)
NOPAT = -186.0m (EBIT -185.8m * (1 - -0.07%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 10.45 (Total Current Assets 342.2m / Total Current Liabilities 32.8m)
Debt / Equity = 0.00 (Debt 1.19m / totalStockholderEquity, last quarter 451.4m)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -102.1m / EBITDA -241.2m)
Debt / FCF = 0.59 (negative FCF - burning cash) (Net Debt -102.1m / FCF TTM -174.3m)
Total Stockholder Equity = 521.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.78% (Net Income -216.8m / Total Assets 484.1m)
RoE = -41.58% (Net Income TTM -216.8m / Total Stockholder Equity 521.4m)
RoCE = -35.50% (EBIT -185.8m / Capital Employed (Equity 521.4m + L.T.Debt 2.15m))
RoIC = -34.14% (negative operating profit) (NOPAT -186.0m / Invested Capital 544.8m)
WACC = 5.74% (E(424.8m)/V(425.9m) * Re(5.76%) + (debt cost/tax rate unavailable))
Discount Rate = 5.76% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 17.43%
Fair Price DCF = unknown (Cash Flow -174.3m)
EPS Correlation: 8.81 | EPS CAGR: -7.74% | SUE: 0.89 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for CGEM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle